首页> 外文期刊>BMC Infectious Diseases >Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia
【24h】

Radiologic findings as a determinant and no effect of macrolide resistance on clinical course of Mycoplasma pneumoniae pneumonia

机译:放射学结果可作为大环内酯类药物耐药性对肺炎支原体肺炎临床病程的决定因素,无影响

获取原文
           

摘要

Background With the emergence of macrolide resistance, concerns about the efficacy of macrolides for the treatment of Mycoplasma pneumoniae (MP) pneumonia in children have been raised. This study aimed to determine the effect of macrolide resistance on the outcome of children who were hospitalized with MP pneumonia. Methods Between 2010 and 2015, we performed culture of MP from nasopharyngeal samples obtained from children who were hospitalized with pneumonia at five hospitals in Korea. Macrolide resistance was determined by the analysis of 23S rRNA gene transition and the minimal inhibitory concentrations of four macrolides. Medical records were reviewed to analyze the clinical response to treatment with macrolides. Results MP was detected in 116 (4.8%) of the 2436 children with pneumonia. MP pneumonia was prevalent in 2011 and 2015. Of the 116 patients with MP pneumonia, 82 (70.7%) were macrolide-resistant. There were no differences in the age distribution, total duration of fever, and chest x-ray patterns between the macrolide-susceptible and macrolide-resistant groups. After macrolide initiation, mean days to defervescence were longer in the macrolide-resistant group than in macrolide-susceptible group (5.7?days vs. 4.1?days, P =?0.021). However, logistic regression analysis revealed that the presence of extrapulmonary signs ( P =?0.039), homogeneous lobar consolidation ( P =?0.004), or parapneumonic effusion ( P?Conclusions This study demonstrated that fever duration in MP pneumonia was determined by the radiologic findings of chest x-ray, not by the presence of macrolide resistance. The results highlight the need for future studies to assess therapeutic benefit from macrolides in the treatment of children with MP pneumonia.
机译:背景技术随着大环内酯类药物耐药性的出现,人们对大环内酯类药物治疗儿童肺炎支原体(MP)肺炎的功效提出了关注。这项研究旨在确定对大环内酯类药物耐药的MP肺炎住院儿童的结局。方法2010年至2015年,我们从韩国五家医院的肺炎住院儿童的鼻咽样本中进行了MP的培养。大环内酯类药物的耐药性通过分析23S rRNA基因转变和四种大环内酯类药物的最低抑菌浓度来确定。审查病历以分析对大环内酯类药物治疗的临床反应。结果在2436名肺炎患儿中,有116名(4.8%)被检出MP。 MP肺炎在2011年和2015年普遍存在。在116例MP肺炎患者中,有82例(70.7%)对大环内酯类药物耐药。在对大环内酯敏感的人群和对大环内酯耐药的人群之间,年龄分布,发烧总持续时间以及胸部X线照片没有差异。大环内酯类药物启动后,大环内酯类药物耐药组的平均去铁天天数比大环内酯类药物敏感组长(5.7?天比4.1?天,P =?0.021)。然而,逻辑回归分析显示,肺外征象(P =?0.039),均质大叶巩固(P =?0.004)或肺炎旁积液(P?)存在。结论本研究表明MP肺炎的发热持续时间由放射学决定结果表明,需要进一步研究评估大环内酯类药物治疗MP肺炎患儿的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号